Further Insights into Type 2 Myocardial Infarction

In Atlanta, Georgia during the spring of 1998, my good friend and colleague, Kristian Thygesen, professor of medicine at Aarhus University in Denmark, and I were having dinner together while attending the annual scientific sessions of the American College of Cardiology. The major topic of conversation that night was the confusing results of two therapeutic clinical trials in acute myocardial infarction. Both trials employed the same intervention but came up with opposite results: One trial reported a positive outcome while the second trial found no benefit.